1
|
Fabbri M, Rousseau V, Corvol JC, Sommet A, Tubach F, De Rycke Y, Bertille N, Selvarasa Y, Carvalho S, Chaigneau V, Brefel-Courbon C, Ory-Magne F, Tessier S, Tir M, Bereau M, Meissner WG, Thiriez C, Marques A, Remy P, Schneider V, Moro E, Defebvre L, Houeto JL, Prange S, Eusebio A, Geny C, Frismand S, Damier P, Reuther CG, Castelnovo G, Benatru I, De Maindreville AD, Drapier S, Maltête D, Lagha-Boukbiza O, Rascol O. Amantadine use in the French prospective NS-Park cohort. J Neural Transm (Vienna) 2024:10.1007/s00702-024-02772-4. [PMID: 38578434 DOI: 10.1007/s00702-024-02772-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Accepted: 03/25/2024] [Indexed: 04/06/2024]
Abstract
OBJECTIVE To assess amantadine use and associated factors in the patients with Parkinson's disease (PD). BACKGROUND Immediate-release amantadine is approved for the treatment of PD and is largely used in clinical practice to treat "levodopa-induced dyskinesia (LIDs). Its use varies according to countries and PD stages. The prospective NS-Park cohort collects features of PD patients followed by 26 French PD Expert Centres. METHODS Variables used for the analyses included demographics, motor and non-motor PD symptoms and motor complications [motor fluctuations (MFs), LIDs)], antiparkinsonian pharmacological classes and levodopa equivalent daily dose (LEDD). We evaluated: (i) prevalence of amantadine use and compared clinical features of amantadine users vs. non-users (cross-sectional analysis); (ii) factors associated with amantadine initiation (longitudinal analysis); (iii) amantadine effect on LIDs, MFs, apathy, impulse control disorders and freezing of gait (Fog) (longitudinal analysis). RESULTS Amantadine use prevalence was 12.6% (1,585/12,542, median dose = 200 mg). Amantadine users were significantly younger, with longer and more severe PD symptoms, greater LEDD and more frequent use of device-aided/surgical treatment. Factors independently associated with amantadine initiation were younger age, longer PD duration, more frequent LIDs, MFs and FoG, higher LEDD and better cognitive function. 9 of the 658 patients on amantadine had stopped it at the following visit, after 12-18 months (1.3%). New users of amantadine presented a higher improvement in LIDs and MF compared to amantadine never users. CONCLUSIONS About 12% of PD patients within the French NS-Park cohort used amantadine, mostly those with younger age and more severe PD. Amantadine initiation was associated with a subsequent reduction in LIDs and MFs.
Collapse
Affiliation(s)
- Margherita Fabbri
- Department of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC1436, Toulouse Parkinson Expert Centre, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), University of Toulouse 3, CHU of Toulouse, INSERM, Toulouse, France.
- Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire-Faculté de Médecine, Toulouse, France.
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France.
| | - Vanessa Rousseau
- Department of Clinical Pharmacology, Clinical Investigation Center CIC1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Jean-Christophe Corvol
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, Inserm, CNRS, Paris, France
- Department of Neurology, Assistance Publique Hôpitaux de Paris, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France
| | - Agnès Sommet
- Department of Clinical Pharmacology, Clinical Investigation Center CIC1436, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Florence Tubach
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Unité de Recherche Clinique PSL-CFX, CIC-1901, F75013, Paris, France
| | - Yann De Rycke
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Unité de Recherche Clinique PSL-CFX, CIC-1901, F75013, Paris, France
| | - Nathalie Bertille
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, Département de Santé Publique, Centre de Pharmacoépidémiologie (Cephepi), Unité de Recherche Clinique PSL-CFX, CIC-1901, F75013, Paris, France
| | - Yajiththa Selvarasa
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, Inserm, CNRS, Paris, France
- Department of Neurology, Assistance Publique Hôpitaux de Paris, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France
| | - Stephanie Carvalho
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, Inserm, CNRS, Paris, France
- Department of Neurology, Assistance Publique Hôpitaux de Paris, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France
| | | | - Christine Brefel-Courbon
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Center, Clinical Investigation Center CIC1436, University Hospital of Toulouse, NeuroToul COEN (Center of Excellence in Neurodegeneration), Toulouse NeuroImaging Center, Inserm, University of Toulouse 3, Toulouse, France
| | - Fabienne Ory-Magne
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Service de Neurologie, Centre Hospitalier Universitaire, Toulouse, Université de Toulouse-Toulouse 3, INSERM, UMR1214 Toulouse NeuroImaging Centre "TONIC," Center of Excellence in Neurodegeneration (CoEN), NeuroToul, Parkinson Expert Center, Clinical Investigation Center CIC1436, Toulouse, France
| | - Samuel Tessier
- Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire-Faculté de Médecine, Toulouse, France
| | - Melissa Tir
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Department of Neurology, University Hospital of Amiens, Amiens, France
| | - Matthieu Bereau
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Department of Neurology, University Hospital of Besançon, Besançon, France
| | - Wassilios G Meissner
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc, NS-Park/FCRIN Network, 33000, Bordeaux, France
- Univ. Bordeaux, CNRS, IMN, UMR5293, 33000, Bordeaux, France
- Dept. Medicine, University of Otago, Christchurch, New Zealand
- New Zealand Brain Research, Christchurch, New Zealand
| | - Claire Thiriez
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Department of Neurology and Parkinson Expert Centre, Caen University-Hospital, Caen, France
| | - Ana Marques
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Neurology Department, Université Clermont Auvergne, EA7280 NPsy-Sydo, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - Philippe Remy
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Centre Expert Parkinson, Neurologie, CHU Henri Mondor, AP-HP, Equipe NPI, IMRB INSERM Et Faculté de Santé, Université Paris-Est Créteil, Créteil, France
| | - Vincent Schneider
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Département de Neurologie, Centre Hospitalier Universitaire François Mitterrand, Université de Bourgogne, Dijon, France
| | - Elena Moro
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Unité des Troubles du Movement, Service de Neurologie, Coordinatrice du Pole PRENELE, CHU de Grenoble, Assesseur Relations Internationales, Faculté de Médécine, Université Grenoble Alpes, President Elect, European Academy of Neurology, Grenoble, France
| | - Luc Defebvre
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Movement Disorders Department, Lille University, Inserm 1172, Lille, France
| | - Jean Luc Houeto
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Department of Neurology, Limoges University Hospital, Inserm, U1094, EpiMaCT-Epidemiology of Chronic Diseases in Tropical Zone, 87042, Limoges Cedex 01, France
| | - Stephane Prange
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Hospices Civils de Lyon, Pierre Wertheimer Neurological Hospital, Expert Parkinson Center, Lyon University, Bron, France
- Université Claude Bernard Lyon 1, Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, Oullins, France
- Marc Jeannerod Institute for Cognitive Neuroscience, CNRS, UMR 5229, Bron, France
| | - Alexandre Eusebio
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Movement Disorders Unit, Neurology Department, University Hospital of Marseille, Marseille, France
| | - Christian Geny
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- EuroMov, Univ. Montpellier, Montpellier, France
- Department of Neurology, CHRU Montpellier, Montpellier, France
| | - Solène Frismand
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Service de Neurologie, Centre Expert Parkinson, Centre Mémoire de Ressources et de Recherche de Lorraine, Hôpital Central Nancy, Nancy, France
| | - Philippe Damier
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Service de Neurologie, CHU Nantes, INSERM, CIC, 1413, Nantes, France
| | - Caroline Giordana Reuther
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Department of Neurology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France
| | - Giovanni Castelnovo
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Department of Neurology, University Hospital of Nîmes, Nîmes, France
| | - Isabelle Benatru
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Departement of Neurology, Poitiers University Hospital, INSERM, CHU de Poitiers, Centre d'Investigation Clinique CIC1402, Poitiers, France
| | - Anne Doe De Maindreville
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Department of Neurology, Hôpital Maison Blanche, Reims, France
| | - Sophie Drapier
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Department of Neurology, Pontchaillou University Hospital, CIC INSERM 1414, Rennes, France
| | - David Maltête
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France
- Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, CEP Rouen, INSERM U1239, Mont-Saint-Aignan, France
| | - Ouhaid Lagha-Boukbiza
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Olivier Rascol
- Department of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC1436, Toulouse Parkinson Expert Centre, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), University of Toulouse 3, CHU of Toulouse, INSERM, Toulouse, France
- Service de Pharmacologie Médicale et Clinique, Centre Hospitalier Universitaire-Faculté de Médecine, Toulouse, France
- French NS-PARK/F-CRIN Network, Clermont-Ferrand, France
| |
Collapse
|
2
|
Béreau M, Kibleur A, Servant M, Clément G, Dujardin K, Rolland AS, Wirth T, Lagha-Boukbiza O, Voirin J, Santin MDN, Hainque E, Grabli D, Comte A, Drapier S, Durif F, Marques A, Eusebio A, Azulay JP, Giordana C, Houeto JL, Jarraya B, Maltete D, Rascol O, Rouaud T, Tir M, Moreau C, Danaila T, Prange S, Tatu L, Tranchant C, Corvol JC, Devos D, Thobois S, Desmarets M, Anheim M. Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson's disease. Brain 2024; 147:472-485. [PMID: 37787488 DOI: 10.1093/brain/awad324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 07/13/2023] [Accepted: 08/21/2023] [Indexed: 10/04/2023] Open
Abstract
Postoperative apathy is a frequent symptom in Parkinson's disease patients who have undergone bilateral deep brain stimulation of the subthalamic nucleus. Two main hypotheses for postoperative apathy have been suggested: (i) dopaminergic withdrawal syndrome relative to postoperative dopaminergic drug tapering; and (ii) direct effect of chronic stimulation of the subthalamic nucleus. The primary objective of our study was to describe preoperative and 1-year postoperative apathy in Parkinson's disease patients who underwent chronic bilateral deep brain stimulation of the subthalamic nucleus. We also aimed to identify factors associated with 1-year postoperative apathy considering: (i) preoperative clinical phenotype; (ii) dopaminergic drug management; and (iii) volume of tissue activated within the subthalamic nucleus and the surrounding structures. We investigated a prospective clinical cohort of 367 patients before and 1 year after chronic bilateral deep brain stimulation of the subthalamic nucleus. We assessed apathy using the Lille Apathy Rating Scale and carried out a systematic evaluation of motor, cognitive and behavioural signs. We modelled the volume of tissue activated in 161 patients using the Lead-DBS toolbox and analysed overlaps within motor, cognitive and limbic parts of the subthalamic nucleus. Of the 367 patients, 94 (25.6%) exhibited 1-year postoperative apathy: 67 (18.2%) with 'de novo apathy' and 27 (7.4%) with 'sustained apathy'. We observed disappearance of preoperative apathy in 22 (6.0%) patients, who were classified as having 'reversed apathy'. Lastly, 251 (68.4%) patients had neither preoperative nor postoperative apathy and were classified as having 'no apathy'. We identified preoperative apathy score [odds ratio (OR) 1.16; 95% confidence interval (CI) 1.10, 1.22; P < 0.001], preoperative episodic memory free recall score (OR 0.93; 95% CI 0.88, 0.97; P = 0.003) and 1-year postoperative motor responsiveness (OR 0.98; 95% CI 0.96, 0.99; P = 0.009) as the main factors associated with postoperative apathy. We showed that neither dopaminergic dose reduction nor subthalamic stimulation were associated with postoperative apathy. Patients with 'sustained apathy' had poorer preoperative fronto-striatal cognitive status and a higher preoperative action initiation apathy subscore. In these patients, apathy score and cognitive status worsened postoperatively despite significantly lower reduction in dopamine agonists (P = 0.023), suggesting cognitive dopa-resistant apathy. Patients with 'reversed apathy' benefited from the psychostimulant effect of chronic stimulation of the limbic part of the left subthalamic nucleus (P = 0.043), suggesting motivational apathy. Our results highlight the need for careful preoperative assessment of motivational and cognitive components of apathy as well as executive functions in order to better prevent or manage postoperative apathy.
Collapse
Affiliation(s)
- Matthieu Béreau
- Department of Neurology, NS-PARK/F-CRIN network, University Hospital of Besançon, 25030 Besançon Cedex, France
- UR LINC 481, Université de Franche-Comté, F-2500 Besançon, France
| | - Astrid Kibleur
- LIP/PC2S, Université Grenoble Alpes, Université Savoie Mont Blanc, 38040 Grenoble Cedex 9, France
| | - Mathieu Servant
- UR LINC 481, Université de Franche-Comté, F-2500 Besançon, France
| | - Gautier Clément
- Department of Neurology, NS-PARK/F-CRIN network, University Hospital of Besançon, 25030 Besançon Cedex, France
| | - Kathy Dujardin
- Lille Neurosciences and Cognition, CHU-Lille, Neurology and Movement Disorders department, NS-Park/F-CRIN network, Univ. Lille, 59037 Lille, France
| | - Anne-Sophie Rolland
- Lille Neurosciences and Cognition, CHU-Lille, Department of Medical Pharmacology, NS-Park/F-CRIN, Univ. Lille, Inserm, 59045 Lille, France
| | - Thomas Wirth
- Service de Neurologie, NS-Park/F-CRIN network, Hôpitaux Universitaires de Strasbourg et Fédération de Médecine Translationnelle de Médecine de Strasbourg, 67200 Strasbourg, France
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM-U964/CNRS-UMR7104/Université de Strasbourg, 67400 Illkirch, France
| | - Ouhaid Lagha-Boukbiza
- Service de Neurologie, NS-Park/F-CRIN network, Hôpitaux Universitaires de Strasbourg et Fédération de Médecine Translationnelle de Médecine de Strasbourg, 67200 Strasbourg, France
| | - Jimmy Voirin
- Department of Neurosurgery, NS-PARK/F-CRIN network, Strasbourg University Hospital, 67200 Strasbourg, France
| | - Marie des Neiges Santin
- Department of Neurosurgery, NS-PARK/F-CRIN network, Strasbourg University Hospital, 67200 Strasbourg, France
| | - Elodie Hainque
- Assistance publique Hôpitaux de Paris, Inserm, CNRS, Hôpital Pitié-Salpêtrière, Department of Neurology, NS-Park/F-CRIN network, Sorbonne Université, Paris Brain Institute-ICM, 75014 Paris, France
| | - David Grabli
- Assistance publique Hôpitaux de Paris, Inserm, CNRS, Hôpital Pitié-Salpêtrière, Department of Neurology, NS-Park/F-CRIN network, Sorbonne Université, Paris Brain Institute-ICM, 75014 Paris, France
| | - Alexandre Comte
- UR LINC 481, Université de Franche-Comté, F-2500 Besançon, France
- Centre d'investigation clinique Inserm CIC 1431, CHU Besançon, F-25000 Besançon, France
| | - Sophie Drapier
- Department of Neurology, NS-PARK/F-CRIN network, University Hospital of Rennes, 35000 Rennes, France
| | - Franck Durif
- CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand University Hospital, Neurology department, NS-Park/F-CRIN network, Université Clermont Auvergne, 63000 Clermont-Ferrand, France
| | - Ana Marques
- CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand University Hospital, Neurology department, NS-Park/F-CRIN network, Université Clermont Auvergne, 63000 Clermont-Ferrand, France
| | - Alexandre Eusebio
- Department of Neurology and Movement Disorders, APHM, Hôpital Universitaire Timone, 13005 Marseille, France
- CNRS, Institut de Neurosciences de la Timone, Aix Marseille Univ., 13005 Marseille, France
| | - Jean-Philippe Azulay
- Department of Neurology and Movement Disorders, APHM, Hôpital Universitaire Timone, 13005 Marseille, France
- CNRS, Institut de Neurosciences de la Timone, Aix Marseille Univ., 13005 Marseille, France
| | - Caroline Giordana
- Department of Neurology, NS-Park/F-CRIN network, Centre Hospitalier Universitaire de Nice, 06002 Nice, France
| | - Jean-Luc Houeto
- Department of Neurology, NS-Park/F-CRIN network, Limoges University Hospital, Inserm, U1094, EpiMaCT-Epidemiology of chronic diseases in tropical zone, Limoges University Hospital,87042 Limoges, France
| | - Béchir Jarraya
- Neuroscience Pole, NS-Park/F-CRIN network, Hôpital Foch, Suresnes, University of Versailles Paris-Saclay, INSERM-CEA NeuroSpin, 91191 Gif-sur-Yvette, France
| | - David Maltete
- Department of Neurology, NS-Park/F-CRIN network, Rouen University Hospital and University of Rouen, 76000 Rouen, France
- INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, 76130 Mont-Saint-Aignan, France
| | - Olivier Rascol
- Department of Clinical Pharmacology and Neuroscience, CIC1436, NS-Park/F-CRIN network, NeuroToul Center of Excellence, Toulouse University Hospital, INSERM, CHU of Toulouse, 31000 Toulouse, France
| | - Tiphaine Rouaud
- Department of Neurology, Centre Expert Parkinson, NS-Park/F-CRIN network, CHU Nantes, 44093 Nantes, France
| | - Mélissa Tir
- Department of Neurology, NS-Park/F-CRIN network, Amiens University Hospital, 80000 Amiens, France
| | - Caroline Moreau
- Lille Neurosciences and Cognition, CHU-Lille, Neurology and Movement Disorders department, NS-Park/F-CRIN network, Univ. Lille, 59037 Lille, France
| | - Teodor Danaila
- Department of Neurology, NS-Park/F-CRIN network, Amiens University Hospital, 80000 Amiens, France
| | - Stéphane Prange
- Department of Neurology, NS-Park/F-CRIN network, Amiens University Hospital, 80000 Amiens, France
- Service de Neurologie C, NS-Park/F-CRIN network, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, 69500 Bron, France
| | - Laurent Tatu
- Department of Neurology, NS-PARK/F-CRIN network, University Hospital of Besançon, 25030 Besançon Cedex, France
| | - Christine Tranchant
- Service de Neurologie, NS-Park/F-CRIN network, Hôpitaux Universitaires de Strasbourg et Fédération de Médecine Translationnelle de Médecine de Strasbourg, 67200 Strasbourg, France
| | - Jean-Christophe Corvol
- Assistance publique Hôpitaux de Paris, Inserm, CNRS, Hôpital Pitié-Salpêtrière, Department of Neurology, NS-Park/F-CRIN network, Sorbonne Université, Paris Brain Institute-ICM, 75014 Paris, France
| | - David Devos
- Lille Neurosciences and Cognition, CHU-Lille, Neurology and Movement Disorders department, NS-Park/F-CRIN network, Univ. Lille, 59037 Lille, France
- Lille Neurosciences and Cognition, CHU-Lille, Department of Medical Pharmacology, NS-Park/F-CRIN, Univ. Lille, Inserm, 59045 Lille, France
| | - Stephane Thobois
- Service de Neurologie C, NS-Park/F-CRIN network, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, 69500 Bron, France
- Institut des Sciences Cognitives Marc Jeannerot, CNRS, UMR5229, 69675 Bron, France
| | - Maxime Desmarets
- Centre d'investigation clinique Inserm CIC 1431, CHU Besançon, F-25000 Besançon, France
- Université de Franche-Comté, EFS, INSERM, UMR RIGHT, 25000 Besançon, France
| | - Mathieu Anheim
- Service de Neurologie, NS-Park/F-CRIN network, Hôpitaux Universitaires de Strasbourg et Fédération de Médecine Translationnelle de Médecine de Strasbourg, 67200 Strasbourg, France
- Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM-U964/CNRS-UMR7104/Université de Strasbourg, 67400 Illkirch, France
| |
Collapse
|
3
|
Landsberger H, Anheim M, Wirth T, Lagha-Boukbiza O, Tranchant C. Efficacité et tolérance du traitement par pompe à apomorphine dans la maladie de Parkinson : étude en vie réelle sur une cohorte strasbourgeoise. Rev Neurol (Paris) 2023. [DOI: 10.1016/j.neurol.2023.01.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
4
|
Clément G, Wirth T, Lagha-Boukbiza O, Voirin J, Philipps C, Longato N, Anheim M. Le langage et les fluences verbales après stimulation cérébrale profonde des noyaux sous-thalamiques dans la maladie de Parkinson. Rev Neurol (Paris) 2023. [DOI: 10.1016/j.neurol.2023.01.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
5
|
Clément G, Wirth T, Haumesser L, Santin MDN, Voirin J, Lagha-Boukbiza O, Labonne C, Tranchant C, Longato N, Phillipps C, Anheim M. Language and verbal fluency outcome after bilateral subthalamic Nucleus Deep Brain Stimulation in Parkinson's disease. Parkinsonism Relat Disord 2022; 105:15-18. [PMID: 36327600 DOI: 10.1016/j.parkreldis.2022.10.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 10/18/2022] [Accepted: 10/23/2022] [Indexed: 11/30/2022]
Abstract
BACKGROUND Language disorders in Parkinson's Disease (PD) following bilateral subthalamic Nucleus Deep Brain Stimulation (STN-DBS) are common. OBJECTIVE To assess STN-DBS impact on language and observe clinical and anatomical predictors of poor outcome. METHODS We prospectively included PD patients undergoing STN-DBS. We performed a neuropsychological evaluation focusing on language before (V0), 3 days after (V1), and 3 months after (V2) surgery. Patients performed all assessments in ON drug condition, V1 with the stimulation turned OFF to evaluate the lesion effect, and V2 with the stimulation turned ON to evaluate the stimulation effect. Electrodes and active contact locations were determined with MRI-Atlas fusion. The stimulation parameters and the total electrical energy delivered (TEED) were recorded for each patient. RESULTS 18 PD patients consecutively operated were included. We identified a decline in phonemic verbal fluency (VFP) at V1 and V2 (p = 0.023 and 0.032 respectively), as well as in semantic verbal fluency (VFS) (p = 0.025 and 0.019, respectively). There was a significant slowdown in the verbs naming test (p = 0.048). No other language alteration was recorded. There was no correlation between demographic or clinical factors and verbal fluency (VF) evolution. Active contact location within substantia nigra was associated with VFP worsening (p = 0.047), while elevated TEED on the left-sided electrode was associated with VFS decline (p = 0.021). CONCLUSION VF was significantly altered following STN-DBS. Location outside the dorsolateral sensorimotor STN, and high stimulation power appeared to promote this decline. Other language domains remained stable.
Collapse
Affiliation(s)
- Guillemette Clément
- Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Thomas Wirth
- Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Inserm-U964/CNRS-UMR7104/, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), France
| | - Lucile Haumesser
- Pôle de Santé Publique, Groupe Méthode en Recherche Clinique, CHU de Strasbourg, France
| | | | - Jimmy Voirin
- Service de Neurochirurgie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Ouhaid Lagha-Boukbiza
- Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Céline Labonne
- Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Christine Tranchant
- Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Inserm-U964/CNRS-UMR7104/, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), France
| | - Nadine Longato
- Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Inserm-U964/CNRS-UMR7104/, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch, France
| | - Clélie Phillipps
- Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Inserm-U964/CNRS-UMR7104/, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch, France
| | - Mathieu Anheim
- Service de Neurologie, Centre de Référence Neurogénétique, Centre Expert Parkinson, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Inserm-U964/CNRS-UMR7104/, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg, Illkirch, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), France.
| |
Collapse
|
6
|
Lamy F, Lagha-Boukbiza O, Wirth T, Philipps C, Longato N, Gebus O, Montaut S, Mengin A, Voirin J, Proust F, Tuzin N, Anheim M, Tranchant C. Early hyperdopaminergic state following sub-thalamic nucleus deep brain stimulation in Parkinson disease. Rev Neurol (Paris) 2022; 178:896-906. [PMID: 36153257 DOI: 10.1016/j.neurol.2022.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 04/26/2022] [Accepted: 07/17/2022] [Indexed: 10/14/2022]
Abstract
BACKGROUND Hyperdopaminergic state (HS), especially impulse control behaviors (ICBs), are not rare in Parkinson's disease (PD). Controversial data regarding HS prevalence one year following sub-thalamic nucleus deep brain stimulation (STN-DBS) are reported. OBJECTIVE Our objectives were to describe early postoperative HS (PoOHS) including ICBs, hypomania and psychotic symptoms during the first 3 months following STN-DBS (V1) and their prognosis at 1 year (V2). METHODS This descriptive study included 24 PD patients treated successively with bilateral STN-DBS between 2017 and 2019. The primary endpoint was prevalence of PoOHS at V1 according to the Ardouin Scale of Behaviour in Parkinson's Disease. RESULTS Prior to STN-DBS (V0), 25% patients had HS (only ICBs) whereas at V1 (during the 3 first months), 10 patients (41.7%) had one or several HS (P=0.22) (de novo in 29.2%): 7 (29.2%) ICBs, 4 (16.7%) hypomanic mood, 1 (4.7%) psychotic symptoms. At V2, all V0 and V1 HS had disappeared, while 1 patient (4.2%) presented de novo HS (P<0.01). No correlation was found between the occurrence of PoOHS at V1 and any V0 data. Higher levodopa equivalent dose of dopamine agonists at V1 was correlated with ICB at V1 (P=0.04). CONCLUSION We found that early PoOHS are frequent in PD after STN-DBS, mostly de novo, with ICBs and hypomania being the most frequent. Despite a good prognosis of PoOHS at one year, our work emphasizes the importance of both a cautious adjustment of dopamine agonist doses and a close non-motor monitoring pre- and post-STN-DBS in PD.
Collapse
Affiliation(s)
- F Lamy
- Service de neurologie, département de neurologie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre, 1, avenue Molière, 67200 Strasbourg cedex, France; Département de neurologie fonctionnelle et d'épileptologie, hospices civils de Lyon, université de Lyon, Lyon, France
| | - O Lagha-Boukbiza
- Service de neurologie, département de neurologie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre, 1, avenue Molière, 67200 Strasbourg cedex, France
| | - T Wirth
- Service de neurologie, département de neurologie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre, 1, avenue Molière, 67200 Strasbourg cedex, France
| | - C Philipps
- Service de neurologie, département de neurologie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre, 1, avenue Molière, 67200 Strasbourg cedex, France
| | - N Longato
- Service de neurologie, département de neurologie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre, 1, avenue Molière, 67200 Strasbourg cedex, France
| | - O Gebus
- Service de neurologie, département de neurologie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre, 1, avenue Molière, 67200 Strasbourg cedex, France
| | - S Montaut
- Service de neurologie, département de neurologie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre, 1, avenue Molière, 67200 Strasbourg cedex, France
| | - A Mengin
- Clinique psychiatrique, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, Strasbourg cedex, France
| | - J Voirin
- Service de neurochirurgie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre, 1, avenue Molière, 67200 Strasbourg cedex, France
| | - F Proust
- Service de neurochirurgie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre, 1, avenue Molière, 67200 Strasbourg cedex, France
| | - N Tuzin
- Département de santé publique, hôpitaux universitaires de Strasbourg, Strasbourg, France
| | - M Anheim
- Service de neurologie, département de neurologie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre, 1, avenue Molière, 67200 Strasbourg cedex, France; Inserm-U964/CNRS-UMR7104, institut de génétique et de biologie moléculaire et cellulaire (IGBMC), université de Strasbourg, Illkirch, France; Fédération de médecine translationnelle de Strasbourg (FMTS), université de Strasbourg, Strasbourg, France
| | - C Tranchant
- Service de neurologie, département de neurologie, hôpitaux universitaires de Strasbourg, hôpital de Hautepierre, 1, avenue Molière, 67200 Strasbourg cedex, France; Inserm-U964/CNRS-UMR7104, institut de génétique et de biologie moléculaire et cellulaire (IGBMC), université de Strasbourg, Illkirch, France; Fédération de médecine translationnelle de Strasbourg (FMTS), université de Strasbourg, Strasbourg, France.
| |
Collapse
|
7
|
Prange S, Lin Z, Nourredine M, Danaila T, Laurencin C, Lagha-Boukbiza O, Anheim M, Klinger H, Longato N, Phillipps C, Voirin J, Polo G, Simon E, Mertens P, Rolland AS, Devos D, Metereau E, Tranchant C, Thobois S. Limbic stimulation drives mania in STN-DBS in Parkinson disease: a prospective study. Ann Neurol 2022; 92:411-417. [PMID: 35703252 DOI: 10.1002/ana.26434] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Revised: 05/30/2022] [Accepted: 06/05/2022] [Indexed: 11/10/2022]
Abstract
In this one-year prospective study, Parkinson's disease (PD) patients with or without mania following STN-DBS were compared to investigate risk and etiological factors, clinical management and consequences. Eighteen (16.2%) out of 111 consecutive PD patients developed mania, of whom 17 were males. No preoperative risk factor was identified. Postoperative mania was related to ventral limbic subthalamic stimulation in 15 (83%) patients, and resolved as stimulation was relocated to the sensorimotor STN, besides discontinuation or reduction of dopamine agonists and use of low-dose clozapine in 12 patients, while motor and nonmotor outcomes were similar. These findings underpin the prominent role of limbic subthalamic stimulation in postoperative mania. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Stéphane Prange
- Univ Lyon, Institut des Sciences Cognitives Marc Jeannerod, CNRS, UMR 5229, Bron, France.,Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson NS-PARK/FCRIN network, Bron, France.,University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Cologne, Germany
| | - Zhengyu Lin
- Service de Neurochirurgie fonctionnelle, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, Hospices Civils de Lyon 59 Bd Pinel, 69500, Bron, France.,Department of Neurosurgery, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.,Center for Functional Neurosurgery, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | | | - Teodor Danaila
- Univ Lyon, Institut des Sciences Cognitives Marc Jeannerod, CNRS, UMR 5229, Bron, France.,Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson NS-PARK/FCRIN network, Bron, France
| | - Chloé Laurencin
- Univ Lyon, Institut des Sciences Cognitives Marc Jeannerod, CNRS, UMR 5229, Bron, France.,Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson NS-PARK/FCRIN network, Bron, France
| | - Ouhaid Lagha-Boukbiza
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - Mathieu Anheim
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch-Graffenstaden, France
| | - Hélène Klinger
- Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson NS-PARK/FCRIN network, Bron, France
| | - Nadine Longato
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Clelie Phillipps
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Jimmy Voirin
- Department of Neurosurgery, NS-PARK/F-CRIN, Strasbourg University Hospital, Strasbourg, France
| | - Gustavo Polo
- Service de Neurochirurgie fonctionnelle, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, Hospices Civils de Lyon 59 Bd Pinel, 69500, Bron, France
| | - Emile Simon
- Service de Neurochirurgie fonctionnelle, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, Hospices Civils de Lyon 59 Bd Pinel, 69500, Bron, France
| | - Patrick Mertens
- Service de Neurochirurgie fonctionnelle, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, Hospices Civils de Lyon 59 Bd Pinel, 69500, Bron, France
| | - Anne-Sophie Rolland
- Univ Lille, CHU-Lille, Medical Pharmacology & Neurology, Expert center for Parkinson, Lille Neuroscience & Cognition, Inserm, UMR-S1172, LICEND, NS-Park network, F-59000, Lille, France
| | - David Devos
- Univ Lille, CHU-Lille, Medical Pharmacology & Neurology, Expert center for Parkinson, Lille Neuroscience & Cognition, Inserm, UMR-S1172, LICEND, NS-Park network, F-59000, Lille, France
| | - Elise Metereau
- Univ Lyon, Institut des Sciences Cognitives Marc Jeannerod, CNRS, UMR 5229, Bron, France.,Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson NS-PARK/FCRIN network, Bron, France
| | - Christine Tranchant
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch-Graffenstaden, France
| | - Stéphane Thobois
- Univ Lyon, Institut des Sciences Cognitives Marc Jeannerod, CNRS, UMR 5229, Bron, France.,Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson NS-PARK/FCRIN network, Bron, France.,Univ Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, Oullins, France
| | | |
Collapse
|
8
|
Wirth T, Méneret A, Lagha-Boukbiza O, Tranchant C, Amélie P, Roze EF, Anheim M. Dyskinésie paroxystique kinésigénique et mutation de novo dans TMEM151A. Rev Neurol (Paris) 2022. [DOI: 10.1016/j.neurol.2022.02.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Schneider V, Wirth T, Iosif AV, Montaut S, Lagha-Boukbiza O, Tranchant C, Anheim M. Intérêt du « signe de la phalange » pour distinguer l’atrophie multi-systématisée de l’ataxie sporadique tardive d’étiologie indéterminée. Rev Neurol (Paris) 2022. [DOI: 10.1016/j.neurol.2022.02.178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
10
|
Prange S, Danaila T, Laurencin C, Lagha-Boukbiza O, Anheim M, Tranchant C, Thobois S. Accès maniaques au décours de la stimulation cérébrale profonde et rôle de la stimulation ventromédiale du noyau subthalamique dans la maladie de Parkinson : une étude prospective. Rev Neurol (Paris) 2022. [DOI: 10.1016/j.neurol.2022.02.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Wirth T, Tranchant C, Drouot N, Keren B, Mignot C, Cif L, Lefaucheur R, Lion-François L, Méneret A, Gras D, Roze E, Laroche C, Burbaud P, Bannier S, Lagha-Boukbiza O, Spitz MA, Laugel V, Bereau M, Ollivier E, Nitschke P, Doummar D, Rudolf G, Anheim M, Chelly J. Increased diagnostic yield in complex dystonia through exome sequencing. Parkinsonism Relat Disord 2020; 74:50-56. [DOI: 10.1016/j.parkreldis.2020.04.003] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 03/27/2020] [Accepted: 04/03/2020] [Indexed: 02/08/2023]
|
12
|
Phillipps C, Longato N, Béreau M, Carrière N, Lagha-Boukbiza O, Mengin AC, Monga B, Defebvre L, Ory-Magne F, Castrioto A, Lhommée E, Rascol O, Krack P, Tranchant C, Corvol JC, Anheim M. Is Motor Side Onset of Parkinson's Disease a Risk Factor for Developing Impulsive-Compulsive Behavior? A Cross-Sectional Study. Mov Disord 2020; 35:1080-1081. [PMID: 32311121 DOI: 10.1002/mds.28053] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Accepted: 03/06/2020] [Indexed: 01/30/2023] Open
Affiliation(s)
- Clélie Phillipps
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - Nadine Longato
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - Matthieu Béreau
- Department of neurology, university hospital of Besançon, Besançon, France
| | - Nicolas Carrière
- U1171, INSERM, Lille University, Lille, France; Neurology Department, Lille University Hospital, Lille, France
| | - Ouhaid Lagha-Boukbiza
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - Amaury C Mengin
- Hôpitaux Universitaires de Strasbourg, Pôle de Psychiatrie, Santé Mentale et Addictologie, 1, place de l'Hôpital, Strasbourg, France; Université de Strasbourg, Faculté de Médecine, Strasbourg, France
| | - Ben Monga
- Faculté de Médecine et Ecole de Santé Publique, Université de Lubumbashi, Lubumbashi, République Démocratique du, Congo
| | - Luc Defebvre
- U1171, INSERM, Lille University, Lille, France; Neurology Department, Lille University Hospital, Lille, France
| | - Fabienne Ory-Magne
- University of Toulouse 3, Centre Hospitalo-Universitaire de Toulouse and INSERM; Centre d'Investigation Clinique CIC1436, Départements de Neurosciences et de Pharmacologie Clinique, NeuroToul COEN center, Toulouse, France
| | - Anna Castrioto
- Movement Disorders Center, Neurology, CHU Grenoble Alpes, Grenoble, France; Université Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France
| | - Eugénie Lhommée
- Movement Disorders Center, Neurology, CHU Grenoble Alpes, Grenoble, France; Université Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France
| | - Olivier Rascol
- Services de Neurologie et de Pharmacologie Clinique, Centre de Reference AMS, Centre d'Investigation Clinique, Réseau NS-Park/FCRIN et Centre of Excellence for Neurodegenerative Disorders (COEN) de Toulouse, CHU de Toulouse, Toulouse 3 University, Toulouse, France
| | - Paul Krack
- Department of Neurology, Division of Movement Disorders, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - Christine Tranchant
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - Jean-Christophe Corvol
- Sorbonne Université, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, ICM, Department of Neurology, Clinical Investigation Center for Neurosciences, Pitié-Salpêtrière Hospital, Paris, France
| | - Mathieu Anheim
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| |
Collapse
|
13
|
Grimaldi S, Renaud M, Robert D, Lagier A, Somma H, Soulayrol S, Korchia D, Fluchère F, Lagha-Boukbiza O, Schaeffer M, Witjas T, Azulay JP, Eusebio A. Prevalence and characterisation of vocal fold motion impairment (VFMI) in patients with Multiple system atrophy compared with Parkinson's disease. Rev Neurol (Paris) 2020; 176:608-613. [PMID: 32164972 DOI: 10.1016/j.neurol.2020.01.351] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Revised: 12/22/2019] [Accepted: 01/02/2020] [Indexed: 01/23/2023]
Abstract
INTRODUCTION Multiple system atrophy (MSA) is a neurodegenerative disorder in which vocal fold mobility can be affected, sometimes leading to life-threatening situations. Our aim was to know if laryngeal examination could help differentiate MSA from Parkinson's disease (PD). MATERIALS AND METHODS Between 2004 to 2014, all consecutive patients diagnosed with probable MSA were included in this retrospective, monocentric study. Flexible laryngoscopy was obtained in 51 MSA patients and compared with 27 patients with Parkinson's disease (PD). Laryngeal muscles EMG was available in 6 MSA patients. RESULTS Vocal fold motion impairments (VFMI) was found in 35 (68.6%) MSA patients: 15 (29.4%) had uni- or bilateral vocal fold abnormal movement (VFAM), 13 (25.5%) had uni- or bilateral vocal fold abductor paresis (VFABP), 4 (7.8%) had uni- or bilateral vocal fold adductor paresis (VFADP), 10 (19.6%) had bilateral vocal fold paralysis (BVFP). VFMI was found in 13 PD patients (48.1%) all of whom had VFADP. Presence of BVFP was found associated with stridor (P<0.001) and dysphagia (P=0.002). In all muscles examined in 6 MSA patients, the EMG showed neuropathic patterns. CONCLUSIONS Our data support that VFMI may be encountered in two-thirds of MSA with a variable degree of gravity. Laryngological examination should be considered as a supplementary tool for the diagnosis and prognosis of MSA. VFMI in particular VFAM, VFABD and BVFP should be discussed as an additional possible red flag even at an early stage of MSA and could help discriminate MSA from PD.
Collapse
Affiliation(s)
- S Grimaldi
- Department of Neurology and Movement Disorders APHM Timone, 13005 Marseille, France.
| | - M Renaud
- Service de génétique clinique, hôpitaux de Brabois, CHU de Nancy, 54500 Vandœuvre-lès-Nancy, France.
| | - D Robert
- Otolaryngology, APHM Conception, 13005 Marseille, France.
| | - A Lagier
- Otolaryngology, APHM Conception, 13005 Marseille, France.
| | - H Somma
- Department of Clinical Neurophysiology, APHM Nord, 13015 Marseille, France.
| | - S Soulayrol
- Department of Neurology and Movement Disorders APHM Timone, 13005 Marseille, France.
| | - D Korchia
- Otolaryngology, APHM Conception, 13005 Marseille, France.
| | - F Fluchère
- Department of Neurology and Movement Disorders APHM Timone, 13005 Marseille, France.
| | - O Lagha-Boukbiza
- Department of Neurology, CHRU Strasbourg, 67098 Strasbourg, France.
| | - M Schaeffer
- Département d'informations médicales, CHRU Strasbourg, 67098 Strasbourg, France.
| | - T Witjas
- Department of Neurology and Movement Disorders APHM Timone, 13005 Marseille, France.
| | - J-P Azulay
- Department of Neurology and Movement Disorders APHM Timone, 13005 Marseille, France.
| | - A Eusebio
- Department of Neurology and Movement Disorders APHM Timone, 13005 Marseille, France.
| |
Collapse
|
14
|
Carré G, Dietemann JL, Gebus O, Montaut S, Lagha-Boukbiza O, Wirth T, Kremer S, Namer IJ, Anheim M, Tranchant C. Brain MRI of multiple system atrophy of cerebellar type: a prospective study with implications for diagnosis criteria. J Neurol 2020; 267:1269-1277. [PMID: 31938861 DOI: 10.1007/s00415-020-09702-w] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Revised: 01/07/2020] [Accepted: 01/09/2020] [Indexed: 11/27/2022]
Abstract
AIM The second consensus statement for the diagnosis of multiple system atrophy type cerebellar (MSA-C) includes pons and middle cerebellar peduncle (MCP) atrophy as MRI features. However, other MRI abnormalities such as MCP hyperintensity, hot cross bun sign (HCB), putaminal hypointensity and hyperintense putaminal rim have been described. OBJECTIVES To evaluate, in patients with sporadic late-onset cerebellar ataxia (SLOCA), the discriminative value of several MRI features for the diagnosis of MSA-C, to follow their evolution during the course of MSA-C, and to search for correlations between these MRI features and clinical signs. METHODS Consecutive patients referred for SLOCA underwent comprehensive clinical evaluation and laboratory investigations, brain MRI, DaTscan and a 1-year follow-up. RESULTS Among 80 patients, 26 had MSA-C, 22 another diagnosis, and 32 no diagnosis at the end of the follow-up. At baseline, MCP hyperintensity and HCB were more frequent in patients finally diagnosed with MSA-C than in other patients with SLOCA (p < 0.0001), and had the highest specificity (98.5%) and positive predictive value (91.7%) for the diagnosis of MSA-C, compared to all other MRI signs. The most relevant MRI sequence regarding HCB sign was the T2-proton density (DP) weighted. All MRI features were more frequent with disease duration. No correlation was found between any MRI feature and neither clinical data, nor dopaminergic neuronal loss (p = 0.5008), except between vermis atrophy and UPDRSIII score. CONCLUSION MCP hyperintensity and HCB sign should be added into the list of additional features of possible MSA-C. MRI signal abnormalities suggestive of MSA-C should be searched for in suitable sequence.
Collapse
Affiliation(s)
- G Carré
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098 Cedex, Strasbourg, France
- Service de Neurologie, Hôpitaux Civils de Colmar, Hôpital Louis Pasteur, 39 avenue de la Liberté, 68024, Colmar, France
| | - J L Dietemann
- Service d'imagerie 2, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098 Cedex, Strasbourg Cedex, France
| | - O Gebus
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098 Cedex, Strasbourg, France
| | - S Montaut
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098 Cedex, Strasbourg, France
| | - O Lagha-Boukbiza
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098 Cedex, Strasbourg, France
| | - T Wirth
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098 Cedex, Strasbourg, France
| | - S Kremer
- Service d'imagerie 2, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098 Cedex, Strasbourg Cedex, France
| | - I J Namer
- Service de Médecine Nucléaire, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098 Cedex, Strasbourg, France
| | - M Anheim
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098 Cedex, Strasbourg, France
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
- Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France
| | - C Tranchant
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, 1 avenue Molière, 67098 Cedex, Strasbourg, France.
- Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
- Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.
| |
Collapse
|
15
|
Cormier-Dequaire F, Bekadar S, Anheim M, Lebbah S, Pelissolo A, Krack P, Lacomblez L, Lhommée E, Castrioto A, Azulay JP, Defebvre L, Kreisler A, Durif F, Marques-Raquel A, Brefel-Courbon C, Grabli D, Roze E, Llorca PM, Ory-Magne F, Benatru I, Ansquer S, Maltête D, Tir M, Krystkowiak P, Tranchant C, Lagha-Boukbiza O, Lebrun-Vignes B, Mangone G, Vidailhet M, Charbonnier-Beaupel F, Rascol O, Lesage S, Brice A, Tezenas du Montcel S, Corvol JC. Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease. Mov Disord 2018; 33:1878-1886. [PMID: 30444952 DOI: 10.1002/mds.27519] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2018] [Revised: 07/18/2018] [Accepted: 09/04/2018] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Impulse control disorders are frequently associated with dopaminergic therapy in Parkinson's disease. Genetic studies have suggested a high heritability of impulse control disorders in the general population and in PD. The aim of this study was to identify candidate gene variants associated with impulse control disorders and related behaviors in PD. METHODS We performed a multicenter case-control study in PD patients with (cases) or without impulse control disorders and related behaviors despite significant dopamine agonist exposure of >300 mg levodopa-equivalent daily dose during 12 months (controls). Behavioral disorders were assessed using the Ardouin scale. We investigated 50 variants in 24 candidate genes by a multivariate logistic regression analysis adjusted for sex and age at PD onset. RESULTS The analysis was performed on 172 cases and 132 controls. Cases were younger (60 ± 8 vs 63 ± 8 years; P < 0.001) and had a higher family history of pathological gambling (12% vs 5%, P = 0.03). No variant was significantly associated with impulse control disorders or related behaviors after correction for multiple testing, although the 2 top variants were close to significant (OPRM1 rs179991, OR, 0.49; 95%CI, 0.32-0.76; P = 0.0013; Bonferroni adjusted P = 0.065; DAT1 40-base pair variable number tandem repeat, OR, 1.82; 95%CI, 1.24-2.68; P = 0.0021; Bonferroni adjusted P = 0.105). CONCLUSIONS Our results are suggestive of a novel association of the opioid receptor gene OPRM1 with impulse control disorders and related behaviors in PD and confirm a previous association with DAT1. Although replication in independent studies is needed, our results bring potential new insights to the understanding of molecular mechanisms of impulse control disorders. © 2018 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Florence Cormier-Dequaire
- Sorbonne Universités, UMR_S1127, ICM, F-75013, Paris, France.,INSERM, UMR_S1127, Paris, France.,CNRS, UMR_7225, Paris, France.,Assistance Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Department of Neurology, CIC-1422, NS-PARK/FCRIN network, Paris, France
| | - Samir Bekadar
- Sorbonne Universités, UMR_S1127, ICM, F-75013, Paris, France.,INSERM, UMR_S1127, Paris, France.,CNRS, UMR_7225, Paris, France
| | - Mathieu Anheim
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | - Said Lebbah
- Assistance Publique Hôpitaux de Paris, Clinical Research Unit, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Antoine Pelissolo
- Assistance Publique Hôpitaux de Paris, Hôpitaux universitaires Henri-Mondor, DHU PePSY, Service de Psychiatrie; INSERM, U955, team 15; UPEC, Université Paris-Est, Faculté de Médecine, Créteil, France
| | - Paul Krack
- Service de Neurologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.,Grenoble Alpes University, Grenoble, France.,Grenoble Institut des Neurosciences, INSERM U1216, Grenoble, France.,Department of Basic Neurosciences, Medical Faculty, University of Geneva, and Clinic of Neurology, Department of Clinical Neurosciences, Geneva University Hospital, Geneva, Switzerland
| | - Lucette Lacomblez
- Sorbonne Universités, UMR_S1127, ICM, F-75013, Paris, France.,Assistance Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Department of Neurology, CIC-1422, NS-PARK/FCRIN network, Paris, France.,Assistance Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Service de Pharmacologie and Regional Pharmacovigilance Center, Paris, France
| | - Eugénie Lhommée
- Service de Neurologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.,Grenoble Alpes University, Grenoble, France.,Grenoble Institut des Neurosciences, INSERM U1216, Grenoble, France
| | - Anna Castrioto
- Service de Neurologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.,Grenoble Alpes University, Grenoble, France.,Grenoble Institut des Neurosciences, INSERM U1216, Grenoble, France
| | - Jean-Philippe Azulay
- Assistance Publique Hôpitaux de Marseille, CHU Timone, Service de neurologie et pathologie du mouvement, Marseille, France; CNRS, institut de neurosciences de la Timone, Aix-Marseille université, UMR 7289, Marseille, France
| | - Luc Defebvre
- Université de Lille, faculté de médecine, CHRU de Lille, centre expert Parkinson, hôpital Salengro, service de neurologie et pathologie du mouvement, Lille, France.,INSERM, U 1171, NS-PARK/FCRIN Network, Lille, France
| | - Alexandre Kreisler
- Université de Lille, faculté de médecine, CHRU de Lille, centre expert Parkinson, hôpital Salengro, service de neurologie et pathologie du mouvement, Lille, France.,INSERM, UMR-S 1172; team "early stages of Parkinson's disease,", Lille, France
| | - Franck Durif
- Centre Hospitalo-Universitaire de Clermont-Ferrand, Department of Neurology, NS-PARK/FCRIN Network, Clermont-Ferrand, France
| | - Ana Marques-Raquel
- Centre Hospitalo-Universitaire de Clermont-Ferrand, Department of Neurology, NS-PARK/FCRIN Network, Clermont-Ferrand, France
| | - Christine Brefel-Courbon
- University of Toulouse 3, University Hospital of Toulouse, INSERM; Departments of Neurosciences and Clinical Pharmacology, Clinical Investigation Center CIC 1436, Toulouse Parkinson Expert Center, NS-Park/FCRIN Network and NeuroToul Center of Excellence for Neurodegenerative Disorders (COEN), Toulouse, France
| | - David Grabli
- Sorbonne Universités, UMR_S1127, ICM, F-75013, Paris, France.,INSERM, UMR_S1127, Paris, France.,CNRS, UMR_7225, Paris, France.,Assistance Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Department of Neurology, CIC-1422, NS-PARK/FCRIN network, Paris, France
| | - Emmanuel Roze
- Sorbonne Universités, UMR_S1127, ICM, F-75013, Paris, France.,INSERM, UMR_S1127, Paris, France.,CNRS, UMR_7225, Paris, France.,Assistance Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Department of Neurology, CIC-1422, NS-PARK/FCRIN network, Paris, France
| | - Pierre-Michel Llorca
- CMP B CHU Clermont-Ferrand, EA 7280, Université Clermont Auvergne, Clermont Ferrand, France; Fondation FondaMental, Créteil, France
| | - Fabienne Ory-Magne
- University of Toulouse 3, University Hospital of Toulouse, INSERM; Departments of Neurosciences and Clinical Pharmacology, Clinical Investigation Center CIC 1436, Toulouse Parkinson Expert Center, NS-Park/FCRIN Network and NeuroToul Center of Excellence for Neurodegenerative Disorders (COEN), Toulouse, France
| | - Isabelle Benatru
- CHU de Poitiers, INSERM CIC 1402, Service de Neurophysiologie, Poitiers, France
| | - Solene Ansquer
- CHU de Poitiers, INSERM CIC 1402, Service de Neurologie, Poitiers, France
| | - David Maltête
- Rouen University Hospital, University of Rouen, INSERM U 1073 1, Department of Neurology, Rouen, France
| | - Melissa Tir
- CHU d'Amiens, Service de Neurologie, SFR CAP-Santé (FED 4231), Amiens, France.,Université de Picardie Jules Verne, Laboratoire de Neurosciences Fonctionnelles et Pathologie, Amiens, France
| | - Pierre Krystkowiak
- CHU d'Amiens, Service de Neurologie, SFR CAP-Santé (FED 4231), Amiens, France
| | - Christine Tranchant
- Service de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.,Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.,Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France
| | | | - Bénédicte Lebrun-Vignes
- Assistance Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Service de Pharmacologie and Regional Pharmacovigilance Center, Paris, France
| | - Graziella Mangone
- Sorbonne Universités, UMR_S1127, ICM, F-75013, Paris, France.,INSERM, UMR_S1127, Paris, France.,CNRS, UMR_7225, Paris, France.,Assistance Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Department of Neurology, CIC-1422, NS-PARK/FCRIN network, Paris, France
| | - Marie Vidailhet
- Sorbonne Universités, UMR_S1127, ICM, F-75013, Paris, France.,INSERM, UMR_S1127, Paris, France.,CNRS, UMR_7225, Paris, France.,Assistance Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Department of Neurology, CIC-1422, NS-PARK/FCRIN network, Paris, France
| | | | - Olivier Rascol
- University of Toulouse 3, University Hospital of Toulouse, INSERM; Departments of Neurosciences and Clinical Pharmacology, Clinical Investigation Center CIC 1436, Toulouse Parkinson Expert Center, NS-Park/FCRIN Network and NeuroToul Center of Excellence for Neurodegenerative Disorders (COEN), Toulouse, France
| | - Suzanne Lesage
- Sorbonne Universités, UMR_S1127, ICM, F-75013, Paris, France.,INSERM, UMR_S1127, Paris, France.,CNRS, UMR_7225, Paris, France
| | - Alexis Brice
- Sorbonne Universités, UMR_S1127, ICM, F-75013, Paris, France.,INSERM, UMR_S1127, Paris, France.,CNRS, UMR_7225, Paris, France.,Assistance Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Department of Genetics, NS-PARK/FCRIN Network, Paris, France
| | - Sophie Tezenas du Montcel
- Assistance Publique Hôpitaux de Paris, Clinical Research Unit, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.,INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, U 1136, Paris, France.,Sorbonne Universités, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013, Paris, France.,Assistance Publique Hôpitaux de Paris, Biostatistics, Public Health and Medical information Unit, Groupe Hospitalier Pitié-Salpêtrière, F-75013, Paris, France
| | - Jean-Christophe Corvol
- Sorbonne Universités, UMR_S1127, ICM, F-75013, Paris, France.,INSERM, UMR_S1127, Paris, France.,CNRS, UMR_7225, Paris, France.,Assistance Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Department of Neurology, CIC-1422, NS-PARK/FCRIN network, Paris, France
| | -
- Sorbonne Universités, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F-75013, Paris, France.,Assistance Publique Hôpitaux de Paris, Biostatistics, Public Health and Medical information Unit, Groupe Hospitalier Pitié-Salpêtrière, F-75013, Paris, France
| |
Collapse
|
16
|
Longato N, Phillipps C, Labonne C, Devillard M, Lagha-Boukbiza O, Anheim M, Tranchant C. Troubles du langage consécutifs à la stimulation des noyaux sous-thalamiques dans la maladie de Parkinson. Rev Neurol (Paris) 2015. [DOI: 10.1016/j.neurol.2015.01.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
17
|
Gebus O, Lagha-Boukbiza O, Mallaret M, Renaud-Hodille M, Rudolf G, Tranchant C, Anheim M. Les ataxies cérébelleuses chroniques tardives sporadiques : quelles étiologies ? Rev Neurol (Paris) 2015. [DOI: 10.1016/j.neurol.2015.01.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Phillipps C, Longato N, Bato A, Lagha-Boukbiza O, Anheim M, Tranchant C. Effet de la latéralité des troubles moteurs sur les troubles du contrôle des impulsions dans la maladie de Parkinson idiopathique. Rev Neurol (Paris) 2015. [DOI: 10.1016/j.neurol.2015.01.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Carré G, Mallaret M, Lagha-Boukbiza O, Dietemann J, Namer I, Anheim M, Tranchant C. Malformation d’Arnold Chiari secondaire à une hyperostose de la voûte crânienne révélée par une ataxie cérébelleuse. Rev Neurol (Paris) 2015. [DOI: 10.1016/j.neurol.2015.01.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease. Brain 2015; 138:1271-83. [PMID: 25805645 DOI: 10.1093/brain/awv063] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2014] [Accepted: 01/17/2015] [Indexed: 11/14/2022] Open
Abstract
After more than 50 years of treating Parkinson's disease with l-DOPA, there are still no guidelines on setting the optimal dose for a given patient. The dopamine transporter type 1, now known as solute carrier family 6 (neurotransmitter transporter), member 3 (SLC6A3) is the most powerful determinant of dopamine neurotransmission and might therefore influence the treatment response. We recently demonstrated that methylphenidate (a dopamine transporter inhibitor) is effective in patients with Parkinson's disease with motor and gait disorders. The objective of the present study was to determine whether genetic variants of the dopamine transporter type 1-encoding gene (SLC6A3) are associated with differences in the response to treatment of motor symptoms and gait disorders with l-DOPA and methylphenidate (with respect to the demographic, the disease and the treatment parameters and the other genes involved in the dopaminergic neurotransmission). This analysis was part of a multicentre, parallel-group, double-blind, placebo-controlled, randomized clinical trial of methylphenidate in Parkinson's disease (Protocol ID:2008-005801-20; ClinicalTrials.gov:NCT00914095). We scored the motor Unified Parkinson's Disease Rating Scale and the Stand-Walk-Sit Test before and after a standardized acute l-DOPA challenge before randomization and then after 3 months of methylphenidate treatment. Patients were screened for variants of genes involved in dopamine metabolism: rs28363170 and rs3836790 polymorphisms in the SLC6A3 gene, rs921451 and rs3837091 in the DDC gene (encoding the aromatic L-amino acid decarboxylase involved in the synthesis of dopamine from l-DOPA), rs1799836 in the MAOB gene (coding for monoamine oxidase B) and rs4680 in the COMT gene (coding for catechol-O-methyltransferase). Investigators and patients were blinded to the genotyping data throughout the study. Eighty-one subjects were genotyped and 61 were analysed for their acute motor response to l-DOPA. The SLC6A3 variants were significantly associated with greater efficacy of l-DOPA for motor symptoms. The SLC6A3 variants were also associated with greater efficacy of methylphenidate for motor symptoms and gait disorders in the ON l-DOPA condition. The difference between motor Unified Parkinson's Disease Rating Scale scores for patients with different SLC6A3 genotypes was statistically significant in a multivariate analysis that took account of other disease-related, treatment-related and pharmacogenetic parameters. Our preliminary results suggest that variants of SLC6A3 are genetic modifiers of the treatment response to l-DOPA and methylphenidate in Parkinson's disease. Further studies are required to assess the possible value of these genotypes for (i) guiding l-DOPA dose adaptations over the long term; and (ii) establishing the risk/benefit balance associated with methylphenidate treatment for gait disorders.
Collapse
Affiliation(s)
- Caroline Moreau
- 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 2 INSERM U1171, Lille University, Lille, France
| | - Sayah Meguig
- 3 Department of Molecular Biology and Pathology Centre, Lille University, CHU Lille, Lille, France
| | - Jean-Christophe Corvol
- 4 Sorbonne Universités, UPMC Univ Paris 06, and INSERM UMRS_1127 and CIC_1422, and CNRS UMR_7225, and AP-HP, and ICM, Hôpital Pitié-Salpêtrière, Département des Maladies du Système Nerveux, Paris, France
| | - Julien Labreuche
- 5 Department of Biostatistics, Lille University, CHU Lille, Lille, France
| | - Francis Vasseur
- 5 Department of Biostatistics, Lille University, CHU Lille, Lille, France
| | - Alain Duhamel
- 5 Department of Biostatistics, Lille University, CHU Lille, Lille, France
| | - Arnaud Delval
- 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 2 INSERM U1171, Lille University, Lille, France
| | - Thomas Bardyn
- 3 Department of Molecular Biology and Pathology Centre, Lille University, CHU Lille, Lille, France
| | | | - Nathalie Rouaix
- 3 Department of Molecular Biology and Pathology Centre, Lille University, CHU Lille, Lille, France
| | - Gregory Petyt
- 6 Department of Nuclear Medicine, Lille University, CHU Lille, Lille, France
| | - Christine Brefel-Courbon
- 7 Departments of Clinical Pharmacology and Neurosciences, CIC9302, University Hospital and Paul Sabatier University, Toulouse, France
| | - Fabienne Ory-Magne
- 7 Departments of Clinical Pharmacology and Neurosciences, CIC9302, University Hospital and Paul Sabatier University, Toulouse, France
| | - Dominique Guehl
- 8 Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR CNRS 5293 and CHU de Bordeaux, Bordeaux, France
| | - Alexandre Eusebio
- 9 Department of Neurology and Movement Disorders - APHM Timone University Hospital and Institut de Neurosciences de la Timone, AMU-CNRS UMR 7289, Marseille, France
| | - Valérie Fraix
- 10 Department of Psychiatry and Neurology, CHU Grenoble, Grenoble, France
| | - Pierre-Jean Saulnier
- 11 Department of Movement Disorders and Neurology, Centre d'Investigation Clinique, INSERM CIC 0802, INSERM U1084, Laboratoire de Neurosciences Expérimentales et Cliniques, CHU de Poitiers, Poitiers, France
| | - Ouhaid Lagha-Boukbiza
- 12 Department of Movement Disorders and Neurology, CHU Strasbourg, Strasbourg, France
| | - Frank Durif
- 13 Department of Movement Disorders and Neurology, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Mirela Faighel
- 14 Department of Movement Disorders and Neurology, INSERM, CIC04, CHU Nantes, Nantes, France
| | - Caroline Giordana
- 15 Department of Movement Disorders and Neurology, CHU Nice, Nice, France
| | - Sophie Drapier
- 16 Department of Neurology, EA- 425 Université Rennes 1 et CHU Pontchaillou, CHU Rennes, Rennes, France
| | - David Maltête
- 17 Department of Neurology and INSERM CIC-CRB 0204, Rouen University Hospital, CHU Rouen Rouen, France
| | - Christine Tranchant
- 12 Department of Movement Disorders and Neurology, CHU Strasbourg, Strasbourg, France
| | - Jean-Luc Houeto
- 11 Department of Movement Disorders and Neurology, Centre d'Investigation Clinique, INSERM CIC 0802, INSERM U1084, Laboratoire de Neurosciences Expérimentales et Cliniques, CHU de Poitiers, Poitiers, France
| | - Bettina Debû
- 10 Department of Psychiatry and Neurology, CHU Grenoble, Grenoble, France
| | - Jean-Philippe Azulay
- 9 Department of Neurology and Movement Disorders - APHM Timone University Hospital and Institut de Neurosciences de la Timone, AMU-CNRS UMR 7289, Marseille, France
| | - François Tison
- 8 Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR CNRS 5293 and CHU de Bordeaux, Bordeaux, France
| | - Alain Destée
- 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 18 INSERM U837/6 Lille JPARC, France
| | - Marie Vidailhet
- 6 Department of Nuclear Medicine, Lille University, CHU Lille, Lille, France
| | - Olivier Rascol
- 7 Departments of Clinical Pharmacology and Neurosciences, CIC9302, University Hospital and Paul Sabatier University, Toulouse, France 19 INSERM NS-PARK National Network, France
| | - Kathy Dujardin
- 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 2 INSERM U1171, Lille University, Lille, France
| | - Luc Defebvre
- 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 2 INSERM U1171, Lille University, Lille, France
| | - Régis Bordet
- 2 INSERM U1171, Lille University, Lille, France 18 INSERM U837/6 Lille JPARC, France
| | - Bernard Sablonnière
- 3 Department of Molecular Biology and Pathology Centre, Lille University, CHU Lille, Lille, France
| | - David Devos
- 1 Department of Movement Disorders and Neurology, Lille University, CHU Lille, Lille, France 2 INSERM U1171, Lille University, Lille, France 20 Department of Medical Pharmacology, Lille University, CHU Lille, Lille, France
| | | |
Collapse
|
21
|
Lagha-Boukbiza O, Montaut S, Anheim M, Tranchant C. Complications chirurgicales et nutritionnelles du traitement par Duodopa. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Montaut S, Mallaret M, Lagha-Boukbiza O, Echaniz-Laguna A, Entz Werlé N, Anheim M, Tranchant C. Une encéphalopathie avec anticorps anti-HU associée à un ganglioneuroblastome chez une jeune adulte. Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Mallaret M, Lagha-Boukbiza O, Biskup S, Namer IJ, Rudolf G, Anheim M, Tranchant C. SPG15: a cause of juvenile atypical levodopa responsive parkinsonism. J Neurol 2013; 261:435-7. [PMID: 24366652 DOI: 10.1007/s00415-013-7216-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2013] [Revised: 12/08/2013] [Accepted: 12/10/2013] [Indexed: 11/30/2022]
Affiliation(s)
- Martial Mallaret
- Service de Neurologie, CHU de Strasbourg, Hôpital de Hautepierre, 1, Avenue Molière, 67098, Strasbourg Cedex, France,
| | | | | | | | | | | | | |
Collapse
|
24
|
Perriard J, Lagha-Boukbiza O, Comanescu A, Anheim M, Tranchant C. Toxoplasmose cérébrale compliquant un traitement par rituximab introduit dans le cadre d’une myasthénie auto-immune sévère. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
25
|
Lagha-Boukbiza O, Perriard J, Schultz P, Anheim M, Tranchant C. Prise en charge du stridor dans l’atrophie multisystématisée (AMS). Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Kremer L, Lagha-Boukbiza O, Fleury MC, Lannes B, Echaniz-Laguna A, Mousson De Camaret B, Tranchant C. Ataxie cérébelleuse récessive par mutation de POLG1 : à propos d’une famille. Rev Neurol (Paris) 2012. [DOI: 10.1016/j.neurol.2012.01.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
27
|
Quenardelle V, Lecocq C, Lagha-Boukbiza O, Fleury-Lesaugnier M, Tranchant C. Amyotrophie bulbospinale liée à l’X (ABS-X) de diagnostic retardé. Rev Neurol (Paris) 2012. [DOI: 10.1016/j.neurol.2012.01.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
28
|
Marcel C, Mallaret M, Lagha-Boukbiza O, Kremer S, Echaniz-Laguna A, Tranchant C. L-2-hydroxyglutaric aciduria diagnosed in a young adult with progressive cerebellar ataxia and facial dyskinesia. Rev Neurol (Paris) 2012; 168:187-91. [DOI: 10.1016/j.neurol.2011.06.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2011] [Revised: 06/03/2011] [Accepted: 06/17/2011] [Indexed: 01/27/2023]
|